Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Ola Landgren (Memorial Sloane Kettering Cancer Center, New York, NY) discusses the development of therapies with novel monoclonal antibodies in multiple myeloma, including antibodies that target CD38, CS1 and PD-1.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.